In Lancet Oncology this week, researchers in China report on the efficacy of gefitinib as a maintenance treatment for patients with locally advanced or metastatic non-small-cell lung cancer. The team randomly assigned 296 patients to receive either gefitinib or placebo within three to six week of chemotherapy, and found that progression-free survival was significantly longer with gefitinib compared to placebo.
This Week in Lancet Oncology
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.